EN DE
Watch PT Charlie Hospital Semarang Tbk for free: we tell you when fair value or trend changes.
Data-driven stock valuation

PT Charlie Hospital Semarang Tbk (RSCH) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of PT Charlie Hospital Semarang Tbk stock IDR 208, price IDR 280, that is 25.6% below the price, quality 35 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare ID

PC PT Charlie Hospital Semarang Tbk logo Thin data Nov 10, 2026

PT Charlie Hospital Semarang Tbk

RSCH · JK
Expensive, weak quality

Our calculation puts a fair price 26% below what the stock costs today.

Low debt
Expensive Growth (revenue 3y +51.3 %/yr in IDR)
Fair value 208.21 IDR · Overvalued
Quality 35/100
Loss-making · -13.0% net margin (TTM)
Trails peers (1/10)
Narrow moat 10/100 · thin data
Thin data
Estimate⚠ Small free float
Watch PT Charlie Hospital Semarang Tbk for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

620.00 IDR 117.00 IDR Fair Value 208.21 IDR Aug 2023 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

38‑month range 117.00 IDR – 620.00 IDR · fair‑value band 156.16 IDR – 260.26 IDR · the 280.00 IDR price screens above the 208.21 IDR fair value. As of Nov 10, 2026.

Follow PT Charlie Hospital Semarang Tbk in your weekly email

Every Wednesday you see whether PT Charlie Hospital Semarang Tbk is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

PT Charlie Hospital Semarang Tbk operates private hospitals in Indonesia. It operates through Healthcare Services, Construction Services, and Construction Materials Trading segments.

Show moreShow less

The company's hospitals offer outpatients and inpatient services, including a 24-hour emergency room, specialist polyclinic services, central surgical installation services, intensive care units, Perina, laboratory services, radiology services, pharmacy services, medical checkup and support services, wellness centers, and other supporting facilities.

It also engages in the construction, maintenance, and reconstruction of residential, office, industrial, commercial, healthcare, educational, lodging, entertainment/sports, and other buildings; and trading of construction materials.

The company was founded in 2019 and is headquartered in Kendal, Indonesia. PT Charlie Hospital Semarang Tbk operates as a subsidiary of PT Wahyu Agung.

Stock analysis

PT Charlie Hospital Semarang Tbk (RSCH) currently trades at 280.00 IDR, while our estimate is 208.21 IDR, 26% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 156.16 IDR (bear) to 260.26 IDR (bull), the price of 280.00 IDR sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

PT Charlie Hospital Semarang Tbk reported revenue of 114B IDR in FY2025 versus 33.0B IDR in FY2022, a compound +51.3%/yr. Reported net income was −16.4B IDR in FY2025.

Key figures

Market cap 1.2T IDR (≈ $64.1M) Micro · P/S ratio 9.67 · Net margin −13.0% · Return on equity −12.1% · Return on assets (EBIT) −4.4% (4-year average) · Operating margin −15.4% · Revenue (TTM) 119B IDR · Revenue growth (YoY) +10.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 55% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −4% fair-value upside, at −26%, RSCH screens richer than that median.

Fair Value

Bear 156.16 IDR Fair Value 208.21 IDR Bull 260.26 IDR
Price 280.00 IDR · Downside -25.6%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 35/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 11
How much profit the company makes from its sales and capital
Quality Growth 50
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 73
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 50
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 6
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+135.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+51.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−26.6% (2022) → −9.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

RSCH screens overvalued: fair value 26% below the price. Compare with HCA Healthcare, Inc →

Compare PT Charlie Hospital Semarang Tbk with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 246 stocks

Beats the industry median on 1/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 35 · Bottom 25%
Fair Value upside −25.6% · Below median
Profitability
Return on assets −8.1% · Bottom 25%
Net margin (12 months) −13.0% · Bottom 25%
Operating margin (12 months) −15.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 10.0% · Above median
Balance sheet
Debt / equity 0.29× · Above median

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/B 8.85× · Priciest 25%
P/S (12 months) 9.67× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 33
FUTURE (revenue growth)50 · sector 33
PAST (return on equity)0 · sector 31
HEALTH (low debt)86 · sector 90
DIVIDEND (yield)0 · sector 39

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Fresenius Medical Care AG FMS $22.74 $46.55 +105% vs RSCH
Aier Eye Hospital Group 300015 ¥8.85 ¥10.88 +23% vs RSCH
DaVita Inc DVA $179.28 $218.90 +22% vs RSCH
HCA Healthcare, Inc HCA $504.42 $547.34 +9% vs RSCH
Tenet Healthcare Corporation THC $290.27 $279.20 −4% vs RSCH
The Ensign Group ENSG $185.09 $140.09 −24% vs RSCH
Encompass Health Corporation EHC $142.51 $94.81 −33% vs RSCH
Fresenius SE FRE €53.47 €34.77 −35% vs RSCH
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,550 ₹5,234 −39% vs RSCH
Dr. Sulaiman Al Habib Medical Services Group 4013 214.70 SAR 109.45 SAR −49% vs RSCH

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

PT Charlie Hospital Semarang Tbk: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "PT Charlie Hospital Semarang Tbk Fair Value". https://www.fairvalue-calculator.com/stock/RSCH

Frequently asked questions

Is PT Charlie Hospital Semarang Tbk (RSCH) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 208.21 IDR versus a price of 280.00 IDR, about 26% lower (overvalued).
What is the fair value of RSCH?
Our estimate for PT Charlie Hospital Semarang Tbk is 208.21 IDR (as of Nov 10, 2026), built from audited fundamentals. The current price: 280.00 IDR.
What is the quality score of RSCH?
PT Charlie Hospital Semarang Tbk has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for PT Charlie Hospital Semarang Tbk (RSCH)?
Our calculated price target is the estimate of 208.21 IDR (as of Nov 10, 2026). Cautious scenario 156.16 IDR, optimistic scenario 260.26 IDR. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the PT Charlie Hospital Semarang Tbk stock forecast for 2026?
Our estimate puts fair value at 208.21 IDR, about 26% lower versus a price of 280.00 IDR (overvalued). Cautious scenario 156.16 IDR, optimistic scenario 260.26 IDR. The calculation is refreshed regularly with new filings.
What is the revenue of PT Charlie Hospital Semarang Tbk (RSCH)?
PT Charlie Hospital Semarang Tbk reported trailing-twelve-month revenue of about 119B IDR (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of PT Charlie Hospital Semarang Tbk (RSCH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For PT Charlie Hospital Semarang Tbk it is 208.21 IDR per share (as of Nov 10, 2026), against a price of 280.00 IDR.
Is PT Charlie Hospital Semarang Tbk stock overvalued or undervalued in 2026?
As of Nov 10, 2026, RSCH trades above its calculated fair value: price 280.00 IDR, fair value 208.21 IDR, a gap of about −26% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RSCH?
No. The price is what the market pays today (280.00 IDR); the fair value is what the company's own numbers justify (208.21 IDR). For PT Charlie Hospital Semarang Tbk the two are 71.79 IDR per share apart. That gap is exactly why we show both numbers side by side.
How much is PT Charlie Hospital Semarang Tbk worth?
The market values PT Charlie Hospital Semarang Tbk at about 1.2T IDR (market capitalisation, as of Nov 10, 2026). Per share that is 280.00 IDR; our models calculate a fair value of 208.21 IDR per share.
What do the bullish and bearish scenarios say about RSCH?
Our models span a range for PT Charlie Hospital Semarang Tbk: cautious scenario 156.16 IDR, base 208.21 IDR, optimistic 260.26 IDR per share (as of Nov 10, 2026, price 280.00 IDR). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of PT Charlie Hospital Semarang Tbk (RSCH)?
Balance-sheet figures for PT Charlie Hospital Semarang Tbk (as of Nov 10, 2026): return on equity −12.1%, debt of 0.29 per unit of equity. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is RSCH from its 52-week high?
PT Charlie Hospital Semarang Tbk trades at 280.00 IDR, about 55% below its 52-week high of 620.00 IDR and 12% above the low of 250.00 IDR (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 208.21 IDR is for.
Which stocks are comparable to PT Charlie Hospital Semarang Tbk?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is PT Charlie Hospital Semarang Tbk stock attractive at the current price?
The data as of Nov 10, 2026: price 280.00 IDR, calculated fair value 208.21 IDR (−26%), Quality Score 35/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. PT Charlie Hospital Semarang Tbk itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of PT Charlie Hospital Semarang Tbk (RSCH)?
The closing price on Nov 10, 2026 was 280.00 IDR. Our estimate is 208.21 IDR, about 26% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with PT Charlie Hospital Semarang Tbk right now?
The price sits above even our optimistic bull case (260.26 IDR). The favourable scenario is already priced in. Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of PT Charlie Hospital Semarang Tbk

How large is the market capitalisation of PT Charlie Hospital Semarang Tbk (RSCH)?
The market capitalisation of PT Charlie Hospital Semarang Tbk is 1.2T IDR (≈ $64.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of PT Charlie Hospital Semarang Tbk (RSCH)?
The price-to-sales ratio of PT Charlie Hospital Semarang Tbk is 9.67 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of PT Charlie Hospital Semarang Tbk (RSCH)?
The net margin of PT Charlie Hospital Semarang Tbk is −13.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of PT Charlie Hospital Semarang Tbk (RSCH)?
The return on equity (ROE) of PT Charlie Hospital Semarang Tbk is −12.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of PT Charlie Hospital Semarang Tbk (RSCH)?
On an EBIT basis the return on assets of PT Charlie Hospital Semarang Tbk is −4.4% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of PT Charlie Hospital Semarang Tbk (RSCH)?
The operating margin of PT Charlie Hospital Semarang Tbk is −15.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at PT Charlie Hospital Semarang Tbk (RSCH)?
Revenue at PT Charlie Hospital Semarang Tbk is growing +10.0% versus a year earlier (3y avg +51.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
Free · no account needed

Watch PT Charlie Hospital Semarang Tbk in the live analysis

One click puts PT Charlie Hospital Semarang Tbk on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.